Skip to main content
. Author manuscript; available in PMC: 2014 Mar 17.
Published in final edited form as: J Nucl Med. 2012 Jun 5;53(7):1119–1126. doi: 10.2967/jnumed.112.103465

FIGURE 6.

FIGURE 6

Female WT mice with implanted SSM3 tumors were imaged with 18F-FES and 18F-FFNP on postimplantation day 21 and were treated with vehicle control or fulvestrant (Fulv; 6 per group) after baseline 18F-FFNP imaging. (A and B) Posttreatment 18F-FFNP (A) and 18F-FES (B) imaging was performed on days 25 and 26, respectively. Activity was measured in tumor and muscle. (C) Tumor growth curve analysis (6 per group). Timing of imaging sessions was as follows: postimplantation day 21 = pretreatment 18F-FES and pretreatment 18F-FFNP, day 25 = posttreatment 18F-FFNP, and day 26 = posttreatment 18F-FES. Timing of treatment and imaging sessions is indicated by ↑ and ^, respectively. **P < 0.01. ***P < 0.001. ****P < 0.0001.